

Highlights of This Issue 495

EDITORIAL

- 497** A Vision from the New Editor-in-Chief
Beverly A. Teicher

REVIEW

- 498** What CAR Will Win the CD19 Race?
Alfonso Quintás-Cardama

SMALL MOLECULE THERAPEUTICS

- 507** Maternal Embryonic Leucine Zipper Kinase (MELK), a Potential Therapeutic Target for Neuroblastoma
Alexandre Chlenski, Chanyoung Park, Marija Dobratic, Helen R. Salwen, Brian Budke, Jae-Hyun Park, Ryan Miller, Mark A. Applebaum, Emma Wilkinson, Yusuke Nakamura, Philip P. Connell, and Susan L. Cohn
- 517** The Rolipram–Perillyl Alcohol Conjugate (NEO214) Is a Mediator of Cell Death through the Death Receptor Pathway
Hee-Yeon Cho, Thu Zan Thein, Weijun Wang, Stephen D. Swenson, Rochelle A. Fayngor, Mengting Ou, Nagore I. Marín-Ramos, Axel H. Schönthal, Florence M. Hofman, and Thomas C. Chen
- 531** First-in-Human Phase I Study of an Oral HSP90 Inhibitor, TAS-116, in Patients with Advanced Solid Tumors
Akihiko Shimomura, Noboru Yamamoto, Shunsuke Kondo, Yutaka Fujiwara, Shigenobu Suzuki, Noriko Yanagitani, Atsushi Horiike, Satoru Kitazono, Fumiyooshi Ohyanagi, Toshihiko Doi, Yasutoshi Kuboki, Akihito Kawazoe, Kohei Shitara, Izumi Ohno, Udai Banerji, Raghav Sundar, Shuichi Ohkubo, Elizabeth M. Calleja, and Makoto Nishio
- 541** Antimalarial Drug Pyrimethamine Plays a Dual Role in Antitumor Proliferation and Metastasis through Targeting DHFR and TP
Huijuan Liu, Yuan Qin, Denghui Zhai, Qiang Zhang, Ju Gu, Yuanhao Tang, Jiahuan Yang, Kun Li, Lan Yang, Shuang Chen, Weilong Zhong, Jing Meng, Yanrong Liu, Tao Sun, and Cheng Yang

- 556** The Antitumor Drug LB-100 Is a Catalytic Inhibitor of Protein Phosphatase 2A (PPP2CA) and 5 (PPP5C) Coordinating with the Active-Site Catalytic Metals in PPP5C
Brandon M. D'Arcy, Mark R. Swingle, Cinta M. Papke, Kevin A. Abney, Erin S. Bouska, Aishwarya Prakash, and Richard E. Honkanen
- 567** A Kinase Inhibitor with Anti-Pim Kinase Activity is a Potent and Selective Cytotoxic Agent Toward Acute Myeloid Leukemia
Ronja Bjørnstad, Reidun Aesoy, Øystein Bruserud, Annette K. Brenner, Francis Giraud, Tara Helen Dowling, Gro Gausdal, Pascale Moreau, Stein Ove Døskeland, Fabrice Anizon, and Lars Herfindal

LARGE MOLECULE THERAPEUTICS

- 579** Nanoparticle Delivery of miR-708 Mimetic Impairs Breast Cancer Metastasis
Divya Ramchandani, Seung Koo Lee, Shira Yomtoubian, Myung Shin Han, Ching-Hsuan Tung, and Vivek Mittal
- 592** Blood Interactions, Pharmacokinetics, and Depth-Dependent Ablation of Rat Mammary Tumors with Photoactivatable, Liposomal Doxorubicin
Kevin A. Carter, Dandan Luo, Jumin Geng, Stephan T. Stern, and Jonathan F. Lovell
- 602** Chemically Modified Antisense Oligonucleotide Against ARL4C Inhibits Primary and Metastatic Liver Tumor Growth
Takeshi Harada, Shinji Matsumoto, Suguru Hirota, Hirokazu Kimura, Shinsuke Fujii, Yuuya Kasahara, Hidetoshi Gon, Toshihiko Yoshida, Tomoo Itoh, Naotsugu Haraguchi, Tsunekazu Mizushima, Takehiro Noda, Hidetoshi Eguchi, Satoshi Nojima, Eiichi Morii, Takumi Fukumoto, Satoshi Obika, and Akira Kikuchi

CANCER BIOLOGY AND TRANSLATIONAL STUDIES

- 613** TGF β Blockade Augments PD-1 Inhibition to Promote T-Cell–Mediated Regression of Pancreatic Cancer
Daniel R. Principe, Alex Park, Matthew J. Dorman, Sandeep Kumar, Navin Viswakarma, Jonathan Rubin, Carolina Torres, Ronald McKinney, Hidayatullah G. Munshi, Paul J. Grippo, and Ajay Rana

Table of Contents

- 621** TGF β Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies
María E. Rodríguez-Ruiz, Inmaculada Rodríguez, Lina Mayorga, Tania Labiano, Benigno Barbes, Iñaki Etxeberria, Mariano Ponz-Sarvisé, Arantza Azpilikueta, Elixabet Bolaños, Miguel F. Sanmamed, Pedro Berraondo, Felipe A. Calvo, Mary Helen Barcelos-Hoff, Jose L. Perez-Gracia, and Ignacio Melero
- 632** TSR-033, a Novel Therapeutic Antibody Targeting LAG-3, Enhances T-Cell Function and the Activity of PD-1 Blockade *In Vitro* and *In Vivo*
Srimoyee Ghosh, Geeta Sharma, Jon Travers, Sujatha Kumar, Justin Choi, H. Toni Jun, Marilyn Kehry, Sridhar Ramaswamy, and David Jenkins
- 642** Combined MEK and BCL-2/ X_L Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness
Claudia Iavarone, Ioannis K. Zervantonakis, Laura M. Selfors, Sangeetha Palakurthi, Joyce F. Liu, Ronny Drapkin, Ursula A. Matulonis, Dorothy Hallberg, Victor E. Velculescu, Joel D. Levenson, Deepak Sampath, Gordon B. Mills, and Joan S. Brugge
- 656** Targeting of BRM Sensitizes *BRG1*-Mutant Lung Cancer Cell Lines to Radiotherapy
Erika Zernickel, Ali Sak, Assad Riaz, Diana Klein, Michael Groneberg, and Martin Stuschke
- 667** The Secretome Engages STAT3 to Favor a Cytokine-rich Microenvironment in Mediating Acquired Resistance to FGFR Inhibitors
Xinyi Wang, Jing Ai, Hongyan Liu, Xia Peng, Hui Chen, Yi Chen, Yi Su, Aijun Shen, Xun Huang, Jian Ding, and Meiyu Geng
- 680** Enhancing Chemosensitivity of Breast Cancer Stem Cells by Downregulating SOX2 and ABCG2 Using Wedelolactone-encapsulated Nanoparticles
Sreemanti Das, Pritha Mukherjee, Ranodeep Chatterjee, Zarqua Jamal, and Urmi Chatterji
- 693** Respiratory Capacity and Reserve Predict Cell Sensitivity to Mitochondria Inhibitors: Mechanism-Based Markers to Identify Metformin-Responsive Cancers
Jing Tsong Teh, Wan Long Zhu, Christopher B. Newgard, Patrick J. Casey, and Mei Wang
- 706** KDM5B Promotes Drug Resistance by Regulating Melanoma-Propagating Cell Subpopulations
Xiaoni Liu, Shang-Min Zhang, Meaghan K. McGeary, Irina Krykbaeva, Ling Lai, Daniel J. Jansen, Stephen C. Kales, Anton Simeonov, Matthew D. Hall, Daniel P. Kelly, Marcus W. Bosenberg, and Qin Yan
- 718** A Simple Three-dimensional Hydrogel Platform Enables *Ex Vivo* Cell Culture of Patient and PDX Tumors for Assaying Their Response to Clinically Relevant Therapies
Kolin C. Hribar, Christopher J. Wheeler, Alexey Bazarov, Kunal Varshneya, Ryosuke Yamada, Pdraig Buckley, and Chirag G. Patil
- 726** Germline Variant in *SLCO2B1* and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)
Andrew W. Hahn, David M. Gill, Austin Poole, Roberto H. Nussenzweig, Sara Wilson, James M. Farnham, Robert A. Stephenson, Lisa A. Cannon-Albright, Benjamin L. Maughan, and Neeraj Agarwal

COMPANION DIAGNOSTIC, PHARMACOGENOMIC, AND CANCER BIOMARKERS




AC icon indicates AuthorChoice

For more information please visit www.aacrjournals.org

Table of Contents

ABOUT THE COVER

TGF β signaling is critical for the evasion of immune surveillance in pancreatic ductal adenocarcinoma (PDAC). In this issue, Principe and colleagues explored the efficacy of combined TGF β and immune checkpoint inhibition in murine PDAC. Tumor bearing mice were treated with the TGFBR1 inhibitor Galunisertib and/or anti-PD-1. The combination significantly reduced tumor burden, increased T-cell infiltration, and improved survival. In the corresponding image, they stained the pancreas of a dual-treated animal for the duct marker CK19 (green), and cytotoxic surrogate Granzyme B (red). This affirms an improved anti-tumor immune response, and suggests that agents such as Galunisertib may potentiate immune checkpoint inhibition in PDAC.



Molecular Cancer Therapeutics

18 (3)

Mol Cancer Ther 2019;18:495-729.

Updated version Access the most recent version of this article at:
<http://mct.aacrjournals.org/content/18/3>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://mct.aacrjournals.org/content/18/3>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.